3 results
Approved WMOCompleted
Primary Objective To evaluate long term safety and tolerability of LAI (590 mg) administered once daily (QD) for up to 12 months in subjects who were refractory to standard multi-drug treatment and failed to convert in Study INS-212. Secondary…
Approved WMOCompleted
The primary objective of the study is to demonstrate the BP lowering effect ofaprocitentan when added to standard-of-care in true resistant hypertension subjects.The secondary objectives of the study are• to demonstrate that the effect of…
Approved WMORecruiting
This study will explore the safety, tolerability, PK, immunogenicity, PD, and preliminary efficacy of RO7428731, in participants with newly diagnosed and recurrent EGFRvIII-positive GBM.